Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.
Cardiovascular and Metabolic Disorders Program, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore.|National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, Singapore.|The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK.|National Institute of Health Research University College London Hospitals Biomedical Research Centre, London W1T 7DN, UK.
Derek J
DJ
Hausenloy
Department of Cardiology, Aarhus University Hospital Skejby, DK-8200 Aarhus N, Denmark.
Hans Erik
HE
Botker
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Thomas
T
Engstrom
Department of Cardiology, Lund University, Lund, Sweden.
David
D
Erlinge
Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany.
Gerd
G
Heusch
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.|IIS-Fundación Jiménez Díaz Hospital, Madrid, Spain.
Borja
B
Ibanez
Huntington Medical Research Institutes, Pasadena, CA, USA.|Division of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert A
RA
Kloner
Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Lyon, France.|UMR 1060 (CarMeN), Université Claude Bernard, Lyon, France.
Michel
M
Ovize
The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, UK.|National Institute of Health Research University College London Hospitals Biomedical Research Centre, London W1T 7DN, UK.
Derek M
DM
Yellon
Department of Cardiology, Vall d'Hebron University Hospital and Research Institute, Universitat Autònoma, Pg Vall d'Hebron 119-129, 08035 Barcelona, Spain.
David
D
Garcia-Dorado
D000241:Adenosine / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D003131:Combined Modality Therapy; D003331:Coronary Vessels / Q000502:physiology; D016572:Cyclosporine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods; D057775:Ischemic Postconditioning / Q000379:methods; D008790:Metoprolol / Q000627:therapeutic use; D033681:Mitochondrial Membrane Transport Proteins / Q000502:physiology; D000083162:Mitochondrial Permeability Transition Pore; D015425:Myocardial Reperfusion / Q000009:adverse effects; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000517:prevention & control*; D009569:Nitric Oxide / Q000378:metabolism / Q000627:therapeutic use; D009573:Nitrites / Q000627:therapeutic use; D009712:Nucleotides, Cyclic / Q000378:metabolism; D009842:Oligopeptides / Q000627:therapeutic use; D010091:Oximes / Q000627:therapeutic use; D018579:Patient Selection; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D000072657:ST Elevation Myocardial Infarction / Q000150:complications* / Q000209:etiology / Q000628:therapy; D012632:Secosteroids / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D002316:Cardiotonic Agents; D004791:Enzyme Inhibitors; D033681:Mitochondrial Membrane Transport Proteins; D000083162:Mitochondrial Permeability Transition Pore; D009573:Nitrites; D009712:Nucleotides, Cyclic; D009842:Oligopeptides; D010091:Oximes; D012632:Secosteroids; D014665:Vasodilator Agents; C506540:arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide; C584311:cyclic guanosine monophosphate-adenosine monophosphate; D009569:Nitric Oxide; C549911:3,5-seco-4-norcholestan-5-one oxime-3-ol; D016572:Cyclosporine; D011493:Protein Kinase C; D008790:Metoprolol; D000241:Adenosine